Found: 6
Select item for more details and to access through your institution.
1055-P: The Machine Learning Prediction Model NASHmap Identifies Higher Insulin Resistance in Type 2 Diabetes Mellitus (T2DM) Patients at Risk for Nonalcoholic Steatohepatitis (NASH).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-1055-P
- By:
- Publication type:
- Article
ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S222, doi. 10.1016/j.clml.2018.07.092
- By:
- Publication type:
- Article
ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S314, doi. 10.1016/j.clml.2017.07.115
- By:
- Publication type:
- Article
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 2, p. 219, doi. 10.1111/bjh.14829
- By:
- Publication type:
- Article
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
- Published in:
- Annals of Internal Medicine, 2018, v. 168, n. 7, p. 461, doi. 10.7326/M17-1094
- By:
- Publication type:
- Article
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article